ALS (ALQ) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
20 Oct, 2025Opening remarks and agenda
Meeting declared open with a quorum present; directors and key executives introduced, including new board member Catharine Farrow and outgoing director Tonianne Dwyer.
Procedures for questions and voting explained for both in-person and virtual attendees, with poll voting on all resolutions.
Financial performance review
FY2025 revenue grew 16% to AUD 3 billion; underlying NPAT slightly declined to AUD 312.1 million due to FX and interest costs.
Operating margin (excluding recent acquisitions) was 19.1%; final dividend of AUD 0.197/share, total AUD 0.386/share (AUD 187 million total payout).
Gross capital expenditure was AUD 165 million (5.5% of revenue), with 70% directed to growth initiatives.
Leverage ratio reduced from 2.3x to 1.7x after a AUD 372.5 million equity raise.
Board and executive committee updates
Catharine Farrow appointed as independent NED in March 2025; up for re-election.
Tonianne Dwyer stepping down after nine years; search for her replacement underway.
John Mulcahy to retire at 2026 AGM; succession planning in progress.
Latest events from ALS
- Revenue up 14% to $1.46bn, EBIT up 2.1%, with strong Life Sciences and resilient margins.ALQ
H1 202513 Jan 2026 - 16% revenue growth, strong cash flow, and major lab upgrades funded by equity raise.ALQ
H2 202520 Nov 2025 - Upgraded FY26 guidance targets 6%-8% organic growth and double-digit profit gains.ALQ
H1 202618 Nov 2025 - Digital and AI innovation, disciplined growth, and strong M&A pipeline drive future value.ALQ
Investor Day 202516 Nov 2025 - Minerals volumes decline, but Life Sciences growth offsets, with NPAT down ~5% for H1 FY25.ALQ
Trading Update13 Jun 2025